Резистентность Candida glabrata к эхинокандинам: некоторые аспекты проблемы | КМАХ

Резистентность Candida glabrata к эхинокандинам: некоторые аспекты проблемы

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(4):324-329

​ Веселов А.В.
10.36488/cmac.2019.4.324-329
кандиды C. glabrata эхинокандины резистентность
Раздел
Антибиотикорезистентность
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2019; 21(4):324-329

Аннотация

Инвазивный кандидоз является распространенным, тяжело протекающим и часто трудно поддающимся лечению осложнением у различных категорий пациентов. Несмотря на то что Candida albicans в большинстве случаев сохраняет лидирующие позиции в качестве этиологической причины, такой возбудитель как Candida glabrata становится все более актуальным патогеном, особенно у пациентов с гемобластозами, получавшими до этого терапию азоловыми антимикотиками. Согласно текущим версиям практических рекомендаций, для терапии системных инфекций, вызванных C. glabrata, препаратами выбора являются эхинокандины. Обладая высокой фунгицидной активностью, в отличие от азолов, они позволяют в большинстве случаев достичь клинической эффективности терапии при выделении данного возбудителя. Однако появляются данные, указывающие на селекцию штаммов C. glabrata со сниженной чувствительностью или устойчивостью к эхинокандинам. В данной статье кратко представлены актуальные данные о проблеме устойчивости C. glabrata к препаратам этого класса, а также приведены результаты российских исследований in vitro.

Веселов Александр Валерьевич

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

  • 1. Pfaller M.A., Messer S.A., Moet G.J., Jones R.N., Castanheira M. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008-2009). Int J Antimicrob Agents. 2011;38:65-69. DOI: 10.1016/j.ijantimicag.2011.02.016
  • 2. Montagna M.T., Lovero G., Borghi E., Amato G., Andreoni S., Campion L., et al. Candidemia in intensive care unit: A nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci. 2014;18:661-674. PMID: 24668706
  • 3. Chakrabarti A., Sood P., Rudramurthy S.M., Chen S., Kaur H., Capoor M., et al. Incidence, characteristics and outcome of ICUacquired candidemia in India. Intensive Care Med. 2014;41:285295. DOI: 10.1007/s00134-014-3603-2
  • 4. Diekema D., Arbefeville S., Boyken L., Kroeger J., Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45-48. DOI: 10.1016/j.diagmicrobio.2012.02.001
  • 5. Pfaller M.A., Andes D.R., Diekema D.J., Horn D.L., Reboli A.C., Rotstein C., et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014;9:e101510. DOI: 10.1371/journal.pone.0101510
  • 6. Khatib R., Johnson L.B., Fakih M.G., Riederer K., Briski L. Current trends in candidemia and species distribution among adults: Candida glabrata surpasses C. albicans in diabetic patients and abdominal sources. Mycoses. 2016;59:781-786. DOI: 10.1111/myc.12531
  • 7. Fidel P.L., Vazquez J.A., Sobel J.D. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12:80-96. PMID: 9880475
  • 8. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253-273. DOI: 10.1128/CMR.00076-09
  • 9. Kurtzman C.P. Phylogenetic circumscription of Saccharomyces, Kluyveromyces and other members of the Saccharomycetaceae, and the proposal of the new genera Lachancea, Nakaseomyces, Naumovia, Vanderwaltozyma and Zygotorulaspora. FEMS Yeast Res. 2003;4:233-245. DOI: 10.1016/S1567-1356(03)00175-2
  • 10. Gabaldón T., Fairhead C. Genomes shed light on the secret life of Candida glabrata: not so asexual, not so commensal. Curr Genet. 2019;65(1):93-98. DOI: 10.1007/s00294-018-0867-z
  • 11. Gabaldon T., Carret L. The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata. FEMS Yeast Research. 2016;16. DOI: 10.1093/femsyr/fov110
  • 12. Kiraz N., Dag I., Oz Y., Yamac M., Kiremitci A., Kasifoglu N. Correlation between broth microdilution and disk diffusion methods for antifungal susceptibility testing of caspofungin, voriconazole, amphotericin B, itraconazole and fluconazole against Candida glabrata. J Microbiol Methods. 2010;82:136140. DOI: 10.1016/j.mimet.2010.05.002
  • 13. Bourgeois N., Laurens C., Bertout S., Balard Y., Krasteva D., Rispail P., et al. Assessment of caspofungin susceptibility of Candida glabrata by the Etest(R), CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations. Eur J Clin Microbiol Infect Dis. 2014;33:1247-1252. DOI: 10.1007/s10096-0142069-z
  • 14. Guinea J., Zaragoza O., Escribano P., Martin-Mazuelos E., Peman J., Sanchez-Reus F., et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2014;58:1529-1537. DOI: 10.1128/AAC.02155-13
  • 15. Chapman B., Slavin M., Marriott D., Halliday C., Kidd S., Arthur I., et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72:1103-1108. DOI: 10.1093/jac/dkw422
  • 16. Hou X., Xiao M., Chen S.C., Kong F., Wang H., Chu Y.Z., et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multicenter study. Front Microbiol. 2017;8:880. DOI: 10.3389/fmicb.2017.00880
  • 17. Shields R.K., Kline E.G., Healey K.R., Kordalewska M., Perlin D.S., Nguyen M.H., et al. Spontaneous mutational frequency and FKS mutation rates vary by echinocandin agent against Candida glabrata. Antimicrob Agents Chemother. 2019;63:e1692-18. DOI: 10.1128/AAC.01692-18
  • 18. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jimenez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724-1732. DOI: 10. 1093/cid/cit136
  • 19. Sasso M., Roger C., Lachaud L. Rapid emergence of FKS mutations in Candida glabrata isolates in a peritoneal candidiasis. Med Mycol Case Rep. 2017;16:28-30. DOI: 10.1016/j.mmcr.2017.04.004
  • 20. Shields R.K., Nguyen M.H., Press E.G., Kwa A.L., Cheng S., Du C., et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862-4869. DOI: 10.1128/AAC.00027-12
  • 21. Pham C.D., Iqbal N., Bolden C.B., Kuykendall R.J., Harrison L.H., Farley M.M., et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58:4690-4696. DOI: 10.1128/AAC.03255-14
  • 22. Mazur P., Baginsky W. In vitro activity of 1,3-β-D-glucan synthase requires the GTP-binding protein rho1. J Biol Chem. 1996;271:14604-14609. DOI: 10.1074/jbc.271.24.14604
  • 23. Park S., Kelly R., Kahn J.N., Robles J., Hsu M.J., Register E., et al. Specific substitutions in the echinocandin target fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:3264-3273. DOI: 10.1128/AAC.49.8.3264-3273.2005
  • 24. Katiyar S.K., Alastruey-Izquierdo A., Healey K.R., Johnson M.E., Perlin D.S., Edlind T.D. FkS1 and FkS2 are functionally redundant but differentially regulated in Candida glabrata: Implications for echinocandin resistance. Antimicrob Agents Chemother. 2012;56:6304-6309. DOI: 10.1128/AAC.00813-12
  • 25. Garcia-Effron G., Park S., Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of FKS1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53:112-122. DOI: 10.1128/AAC.01162-08
  • 26. Shields R., Nguyen M., Press E., Updike C., Clancy C. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother. 2013;57(8):35283535. DOI: 10.1128/AAC.00136-13
  • 27. Hou X., Healey K.R., Shor E., Kordalewska M., Ortigosa C.J., Paderu P., et al. Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata. Emerg Microbes Infect. 2019;8(1):1619-1625. DOI: 10.1080/22221751.2019.1684209
  • 28. Lewis J.S., 2nd, Wiederhold N.P., Wickes B.L., Patterson T.F., Jorgensen J.H. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother. 2013;57:4559-4561. DOI: 10.1128/AAC.01144-13
  • 29. Rodrigues C.F., Rodrigues M.E., Silva S., Henriques M. Candida glabrata biofilms: how far have we come? J Fungi. 2017;3:11. DOI: 10.3390/jof3010011
  • 30. Beyda N.D., John J., Kilic A., Alam M.J., Lasco T.M., Garey K.W., et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59:819-825. DOI: 10.1093/cid/ciu407
  • 31. Pfaller M.A., Casanheira M., Lockhart S.R., Ahlquist A.M., Messer S.A., Jones R.N. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;4:1199-1203. DOI: 10.1128/JCM.06112-11
  • 32. Walker L.A., Gow N., Munro C.A. Fungal echinocandin resistance. Fungal Gene Biol. 2010;2:117-126. DOI: 10.1016/j.fgb.2009.09.003
  • 33. Persyn A., Rogiers O., Brock M., Velde G.V., Lamkanfi M., Jacobsen I.D., et al. Monitoring of fluconazole and caspofungin activity against in vivo Candida glabrata biofilms by bioluminescence imaging. Antimicrob Agents Chemother. 2019;63(2). pii: e01555-18. DOI: 10.1128/AAC.01555-18
  • 34. Shields R.K., Nguyen M.H., Clancy C.J. Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis. 2015;28:514-522. DOI: 10.1097/QCO.0000000000000215
  • 35. Pfaller M.A., Diekema D.J., Turnidge J.D., Castanheira M., Jones R.N. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016. Open Forum Infect Dis. 2019;6(Suppl. 1):S79-S94. DOI: 10.1093/ofid/ofy358
  • 36. Klimko N., Vasilyeva N., Chernenkaya T., Kutsevalova O., Vetokhina A., Mukhacheva S., et al. Invasive candidiasis in intensive care units: results of prospective multicenter study in Russia. Proceedings of the 25th ECCMID, Copenhagen, Denmark, April 25-28, 2015. Abstr. EV0945.
  • 37. Klyasova G., Malchikova A., Maschan M., Molchanova I., Kutsevalova O., Chernenkaya T., et al. In vitro activity of echinocandins and azoles against Candida spp. Isolated from hematological (Hem) and non-hematological (non-Hem) patients in 11 centers of Russia. Mycoses. 2017;60(Suppl. 2):65.
  • 38. Veselov A., Vasilyeva N., Raush E., Kutsevalova O., Nighegorodtseva I., Petrova L., et al. Susceptibility of Candida glabrata Isolates to Anidulafungin, Caspofungin, and Micafungin Using Colorimetric Microdilution Test in Russia. Proceedings of ASM Microbe, Atlanta, USA, June 8-10, 2018; Abstr. #508.
  • 39. Veselov A.V., Vasilyeva N.V., Bogomolova T.S., Raush E.R., Kutsevalova O.Yu., Nizhegorodtseva I.A., et al. Susceptibility testing of Candida glabrata clinical strains to echinocandins using SensititreTM YeastOneTM system. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;20(1):49-54. Russian. (Веселов А.В., Васильева Н.В., Богомолова Т.С., Рауш Е.Р., Куцевалова О.Ю., Нижегородцева И.А. и соавт. Определение чувствительности клинических штаммов Candida glabrata к эхинокандинам с помощью системы Sensititre™ YeastOne™. Клиническая микробиология и антимикробная химиотерапия. 2018;20(1):49-54.)
  • 40. Pfaller M.A., Castanheira M. Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. Med Mycol. 2016;54(1):1-22. DOI: 10.1093/mmy/myv076
  • 41. Cornely O., Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl. 7):19-37. DOI: 10.1111/1469-0691.12039
  • 42. Ullmann A., Akova M., Herbrecht R., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl. 7):53-67. DOI: 10.1111/1469-0691.12041
  • 43. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1-e50. DOI: 10.1093/cid/civ933
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились